Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users

被引：0
|
作者：
François Laliberté
Michel Cloutier
Concetta Crivera
Winnie W. Nelson
William H. Olson
Jeffrey Schein
Julie Vanderpoel
Guillaume Germain
Patrick Lefebvre
机构：
[1] Groupe d’analyse,
[2] Ltée,undefined
[3] Janssen Scientific Affairs,undefined
[4] LLC,undefined
来源：
Advances in Therapy | 2015年 / 32卷
关键词：
Anticoagulant agents; Atrial fibrillation; Cost; Rivaroxaban; Warfarin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：216 / 227
页数：11
相关论文
共 50 条
  • [41] THROMBOLYTIC THERAPY IN ANTICOAGULATED PATIENTS: CASE SERIES FROM RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION (ROCKET AF)
    Chen, Sean
    Hellkamp, Anne
    Becker, Richard
    Berkowitz, Scott
    Breithardt, Guenter
    Fox, Keith
    Hacke, Werner
    Halperin, Jonathan
    Hankey, Graeme
    Mahaffey, Kenneth
    Nessel, Christopher
    Piccini, Jonathan
    Singer, Daniel
    Patel, Manesh
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 446 - 446
  • [42] Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
    Peterson, Eric D.
    Ashton, Veronica
    Chen, Yen-Wen
    Wu, Bingcao
    Spyropoulos, Alex C.
    AMERICAN HEART JOURNAL, 2019, 212 : 113 - 119
  • [43] Effectiveness and Safety of Apixaban and Rivaroxaban Versus Warfarin for the Secondary Prevention of Stroke or Systemic Embolism Among Nonvalvular Atrial Fibrillation Patients
    Coleman, Craig
    Bunz, Thomas
    NEUROLOGY, 2017, 88
  • [44] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS WARFARIN FOR TREATMENT OF NONVALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH WORSENING RENAL FUNCTION
    Salcedo, J.
    Hay, J. W.
    Lam, J.
    VALUE IN HEALTH, 2018, 21 : S61 - S61
  • [45] Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
    Chan, Yi-Hsin
    See, Lai-Chu
    Tu, Hui-Tzu
    Yeh, Yung-Hsin
    Chang, Shang-Hung
    Wu, Lung-Sheng
    Lee, Hsin-Fu
    Wang, Chun-Li
    Kuo, Chang-Fu
    Kuo, Chi-Tai
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (08):
  • [46] Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease
    Weir, Matthew R.
    Ashton, Veronica
    Moore, Kenneth T.
    Shrivastava, Shubham
    Peterson, Eric D.
    Ammann, Eric M.
    AMERICAN HEART JOURNAL, 2020, 223 : 3 - 11
  • [47] EFFECTIVENESS AND SAFETY OF APIXABAN AND RIVAROXABAN VERSUS WARFARIN FOR THE SECONDARY PREVENTION OF STROKE OR SYSTEMIC EMBOLISM AMONG NONVALVULAR ATRIAL FIBRILLATION PATIENTS
    Coleman, Craig I.
    Bunz, Thomas J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 458 - 458
  • [48] Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function
    Salcedo, Jonathan
    Hay, Joel W.
    Lam, Jenny
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 282 : 53 - 58
  • [49] Rivaroxaban versus warfarin after atrial fibrillation related stroke
    Hong KS
    Kwon SU
    Lee SH
    中华物理医学与康复杂志, 2017, 39 (11) : 878 - 878
  • [50] Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function
    Weir, Matthew R.
    Haskell, Lloyd
    Berger, Jeffrey S.
    Ashton, Veronica
    Laliberte, Francois
    Crivera, Concetta
    Brown, Kip
    Lefebvre, Patrick
    Schein, Jeffrey
    CLINICAL NEPHROLOGY, 2018, 89 (05) : 314 - 329
12345